The DEA is moving a derivative of cocaine, but stalling in marijuana rescheduling?

DEA is shifting the cocaine-derived drug schedule while marijuana lingers on Schedule I – marijuana moment

The DEA recently re-prescribed a cocaine-derived drug, but is maintaining cannabis as a List I substance despite its medicinal benefits. This step shows that not only the DEA can reschedule drugs quickly – but has also actively worked against cannabis in recent years.

Marijuana Moment outlined finer details of the shift, which we will discuss later in the article. The purpose of this article is threefold;

1. The process of rescheduling a drug on the CSA

2. The validity of the CSA

3. How the DEA actively campaigned against a rescheduling of cannabis

Of course, I don’t think the DEA is the only agency responsible for stifling the advancement of cannabis legalization over the years – but it acted as the spearhead of a bipartisan policy that plagued millions of people over the year Decades.

Let’s first take a look at the recent rescheduling of [18F]FP-CIT.

The rescheduling timeline explained

In 2018, Advanced Imaging Projects filed a petition to “move” the substance. The DEA then spent a few months reviewing and collecting data before forwarding its findings and petition to Health and Human Services (HHS). HHS received all of this information in May 2019.

On April 21st, the HHS and the FDA and NIDA all agreed and determined that the substance does not comply with a Schedule II status or any other status in this regard. What makes the review strange is that the HHS found that the substance appears to be more effective than cocaine on some behavioral evaluations.

FP-CIT “can have a potential for abuse if the dose taken is high enough and the deterrent effect of the extremely low concentration of the available radioligand is not taken into account,” the press release said. – Source marijuana moment

Separately, the DEA found the following;

“Based on the FDA’s scientific and medical review … and its findings regarding the substance’s abuse potential, legitimate medical use, and addiction liability, HHS recommended that.” [18 F]FP-CIT will be deleted from all CSA timetables “,

“The CSA requires the DEA, as delegated by the Attorney General, to determine whether the scientific and medical evaluation of HHS, the planning recommendation, and any other relevant data are material evidence that a substance should be planned. 21 USC 811 (b). DEA has reviewed the scientific and medical evaluation and planning recommendations of the HHS as well as all other relevant data and created its own eight-factor review document [18 F]FP-CIT according to 21 USC 811 (c). “

“On the basis of the scientific and medical evaluation and the accompanying recommendation of HHS and based on the consideration of DEA’s own eight-factor analysis, DEA determines that these facts and all relevant data prove that [18 F]FP-CIT has no potential for abuse or dependency, ”says the press release. “DEA thinks so [18 F]FP-CIT does not meet the requirements for inclusion in a schedule and should be removed from control according to the CSA. “

In other words, it took the DEA, along with the HHS, FDA, and NIDA, only three years to evaluate a cocaine-derived drug, but hasn’t been able to do it for cannabis in 51 years since the Controlled Substance Act was passed in 1970.

Currently, cannabis and psilocybin and other psychedelic drugs – all of which currently show significant therapeutic benefit – are all placed on List I, reserved for drugs with high potential for abuse and with no recognized medical value.

Reschedule and remove completely [18F]The CSA’s FP-CIT lasted a little over four years. It’s things like this that make cannabis activists question the bias of these agencies and whether or not “science” really runs politics.

Does the Narcotics Act work?

To understand why the cocaine drug has been rescheduled and cannabis still remains a List I substance, one simply has to look at the nature of the 1970 Comprehensive Substance Abuse Prevention and Control Act.

You just have to look at the wording of the law, which reads; “With subsequent changes, the Pharmaceutical industry to ensure physical security and strict records of certain types of drugs … “

In other words, the CSA is – one way or another – overseen by the pharmaceutical industry. [18F]FP-CIT is a drug that is primarily manufactured by the pharmaceutical industry and therefore – for the purposes of the pharmaceutical industry – can easily be taken out of schedule.

Compare this to drugs like cannabis, psilocybin, mescaline, etc. – all of which are easily grown at home by the individual. These drugs remove dependence on the pharmaceutical industry from the equation.

That is not to say that the pharmaceutical industry cannot make highly effective drugs from these substances – but it is taking away its monopoly on the distribution and manufacture of drugs. Everyone would have the option of growing it themselves instead of buying it from the pharmacy.

Given that pharmaceuticals have historically put profits above people, it makes perfect sense that cannabis and these other psychedelics are pretty harmless compared to most of the pharmaceutical drugs on the market, although the scientific literature suggests that they are still remain a List I substance.

This also calls into question the very purpose of the CSA. If the CSA is to prevent abuse – some of the most abused drugs currently on the market, however, are pharmaceutical derivatives – the document seems to have failed in its real aim.

Rather, it is a means by which the pharmaceutical industry has managed to maintain its monopoly and sell drugs that are in many cases far worse for the individual than the natural alternatives.

How the DEA was used as a weapon

The DEA is not responsible, it is just the enforcement wing of the pharmaceutical industry. Funding comes direct from the pharmaceutical industry to the FDA, NIDA, and other federal agencies, and if you just study history you can see how drug “rescheduling” has always benefited the pharmaceutical industry.

We have spent more than fifty years capitalizing on these policies that have allowed the pharmaceutical industry to grow to a size where they practically own a large chunk of the Senate. We see the rotating door between government agencies and top positions in the pharmaceutical industry.

If, at this point, you are not even remotely skeptical about the drug decision-making process, you need to realize that the War on Drugs, CSA, and Anti-Drugs Policy are not there for your safety – rather, the safety of them Dominance of the pharmaceutical industry.

THE DEA ABOUT CANNABIS AND MUSHROOMS, READ MORE …

THE DEA WOULD LIKE YOU TO GROW MORE WEED FOR TESTING IN 2022!

OR..

THE DEA WILL TEST MUSHROOMS AND MARIJUANA IN 2022!

The post The DEA is moving a derivative of cocaine, but stalling in marijuana rescheduling? appeared first on fifthavegreenhouse.

Original post here: The DEA is moving a derivative of cocaine, but stalling in marijuana rescheduling?